The obtained results well support the idea that TRF2, despite promoting cancer formation and progression, is able to increase the sensitivity of tumor cells to taxane-based chemotherapy, representing a sort of Achilles' heel for TNBC cells. The gene discussed is TERF2; the disease is neoplasm.